Results of Endovascular Treatment for Infrapopliteal Arterial Occlusive Disease.

Capital Medical University

Status: Enrolling

Conditions: Endovascular Treatment; Infrapopliteal Artery Occlusive Disease

Treatments: Device: Endovascular treatment

Study type: Observational

Funder types: Other

Identifiers

NCT06009146

IPOD-Real Study

Details and patient eligibility

About

This study is a prospective, multi-center observational study, which evaluates the effectiveness and safety of endovascular therapy in the real world for infrapopliteal arterial occlusive disease from intermittent claudication to chronic threatening limb ischemia.

Full description

This study is a prospective, multi-center observational study. This study will be conducted at 38 centers and is expected to enroll more than 3000 patients. And we will evaluate the effectiveness and safety of endovascular therapy in the real world for infrapopliteal arterial occlusive disease from intermittent claudication to chronic threatening limb ischemia.

Enrollment: 3,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients ≥ 18 years of age; Patients with ≥1 infrapopliteal artery disease (P3 popliteal artery, anterior tibial artery, posterior tibial artery, peroneal artery, tibiofibular trunk) need to receive endovascular treatment, regardless of whether there is a combination of supra-knee or submalleolar occlusion; Patients voluntary and capable of follow-up;

Exclusion criteria

Patients who are known to be allergic to heparin, aspirin, other antiplatelet drugs, contrast agents, etc., and those who are unable to undergo endovascular therapy for other reasons; Pregnant and lactating women; Patients with thromboangiitis obliterans；

Trial design

3,000 participants in 3 patient groups

Rutherford scale < 4

Treatment:

Device: Endovascular treatment

Rutherford scale 4-5

Treatment:

Device: Endovascular treatment

Rutherford scale 6

Treatment:

Device: Endovascular treatment